The new Phase 2 clinical trial protocol focuses on a specific patient population (advanced, recurrent, platinum-resistant ovarian cancer patients) with limited treatment options, highlighting the ...

Clinical trial complexity has significantly increased in the past decade. How can the industry adapt and innovate to remain ...

Anixa Biosciences (ANIX) announced that it, along with its partner Moffitt Cancer Center, has received approval for an amendment to the ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Now such calls to make clinical trial data transparent – along with openly accessible protocols, papers, and summary results – are really burgeoning, and it’s easy to lose the plot.

Q3 2025 Management View CEO Jim Frakes noted that Aethlon Medical has made significant progress in focusing on oncology and implementing cost reductions. Operating expenses were reduced by 50% ...

In this video interview, Dominique Demolle, CEO of Cognivia, highlights how patient non-adherence could increase trial ...

There is no need to reinvent the wheel. Look at the protocol with fresh eyes Most patients know little about clinical trial protocols and processes. Even if they understand the clinical trial ...

Yunu manages more than 5,000 active clinical trial protocols and serves as the primary source of imaging endpoint data for over 25% of all NCI-designated cancer centers. The partnership between Yunu ...